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OBJECTIVE — Subclinical inﬂammation is linked with the development of type 2 diabetes,
and epidemiologic data suggest that this association may be stronger in women. Although small
clinicalstudieshaveshownaprominenthypoglycemiceffectofshort-termhigh-doseaspirin,no
randomized trials have directly evaluated the efﬁcacy of aspirin in diabetes prevention at doses
acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin
prevents the development of clinical diabetes among initially healthy American women.
RESEARCH DESIGN AND METHODS — Subjects were enrolled in the Women’s
Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vita-
min E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995,
38,716 women aged 45 years and free of clinical diabetes were randomly assigned to either
low-doseaspirinorplacebo(medianfollow-up10.2years).Documentedclinicaltype2diabetes
was prospectively evaluated throughout the trial.
RESULTS — Among women randomly assigned to receive aspirin (n  19,326) or placebo
(n  19,390), there was no statistically signiﬁcant difference in the incidence of type 2 diabetes.
There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio
1.01 [95% CI 0.91–1.11]). Stratiﬁcation by diabetes risk factors including age, BMI, family
history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not sup-
port a modulating effect of these variables. Analyses accounting for treatment duration and
adherence similarly found no beneﬁcial effects.
CONCLUSIONS — Thesedatasuggestthatlong-termlow-doseaspirindoesnotpreventthe
development of clinical type 2 diabetes in initially healthy women.
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T
he ability of salicylates, such as aspi-
rin, to reduce glucose levels was de-
scribed 125 years ago (1). This
effectwaslargelyforgottenuntiltheemer-
genceofrecentdatalinkinginﬂammation
with the development of type 2 diabetes.
A wealth of experimental and epidemio-
logical evidence now indicates that insu-
lin resistance and type 2 diabetes are, in
part, obesity-linked inﬂammatory disor-
ders (2), and the presence of subclinical
inﬂammation is now known to be a po-
tent indicator of risk for this disease. This
relationship may be of particular impor-
tance in the pathogenesis of diabetes in
women among whom obesity-triggered
inﬂammation may be heightened com-
paredwiththatinmen(3).Theseﬁndings
have spurred interest in the use of anti-
inﬂammatory drugs in diabetes preven-
tion and treatment (4). However, data
pertaining to this novel approach are
sparse with no large-scale randomized
studies available to date.
Aspirin is an anti-inﬂammatory agent
with pleiotropic actions, many of which
remain poorly understood. The cellular
and molecular mechanisms of the hypo-
glycemicresponsetoaspirinareanareaof
active investigation but likely involve
anti-inﬂammatorypathwaysdistinctfrom
effects on prostaglandin synthesis (5,6).
Several small clinical studies (7–10) have
reported that short-term high-dose aspi-
rin (3–10 g/day for 3 days–3 weeks)
improvesglucosehandlingandmayame-
liorate insulin resistance in diabetic pa-
tients, albeit with a high rate of side
effects.Althoughdataarenotavailableon
the hypoglycemic action of low-dose as-
pirin, several short-term clinical trials
demonstrated that aspirin triggers the
production of anti-inﬂammatory media-
tors (11) and lowers systemic levels of in-
ﬂammatory biomarkers at doses as low as
30 mg/day (12). Whether chronic low-
doseaspirintherapyhasfavorableclinical
effects is unknown.
We assessed whether long-term low-
dose aspirin therapy reduces the inci-
dence of clinical type 2 diabetes in the
randomized treatment arms of the Wom-
en’s Health Study (WHS). The WHS
tested the efﬁcacy of low-dose aspirin in
the primary prevention of cardiovascular
disease and cancer over a 10-year period
in a large group of initially healthy
women. The occurrence of clinical diabe-
tes was ascertained prospectively
throughout the trial.
RESEARCH DESIGN AND
METHODS— The WHS was a 2  2
factorial trial evaluating the balance of
risks and beneﬁts of low-dose aspirin
(100 mg every other day; Bayer Health-
care)andvitaminE(600IU-tocopherol
everyotherday;NaturalSourceVitaminE
Association) in the primary prevention of
cardiovascular disease and cancer (13–
15). The dose of 100 mg every other day
was chosen to be the lowest dose that
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while minimizing gastrointestinal side ef-
fects.Althoughnotaprespeciﬁedprimary
end point of the WHS, clinical diabetes
was a key outcome of interest and pro-
spectively ascertained throughout the
duration of the trial.
Written informed consent was ob-
tainedfromallwomen.Thestudywasap-
proved by the institutional review board
of the Brigham and Women’s Hospital
and monitored by an external data and
safety monitoring board.
Setting and participants
Details of the study design have previ-
ously been described (13,16). Women
were eligible if they were at least 45 years
ofagewithoutaprevioushistoryofcancer
(except nonmelanoma skin cancer),
cardiovascular disease, or other major
chronic illness; had no history of adverse
effects from aspirin; were not taking aspi-
rin or nonsteroidal anti-inﬂammatory
drugs (or were willing to forgo their use
during the trial); and were not taking an-
ticoagulants or individual supplements of
vitamin A, E, or -carotene more than
once a week. A total of 39,876 women
were willing, eligible, and compliant dur-
ing a 3-month placebo run-in period and
underwent random assignment: 19,934
were assigned to receive aspirin and
19,942 to receive placebo. In the present
analyses, we excluded women with re-
ported physician-diagnosed diabetes at
baseline (n  1,160), leaving a total of
38,716 women free of clinical diabetes at
entry into the trial; 19,326 were assigned
to receive aspirin and 19,390 to receive
placebo. Additional details including a
Consolidated Standards of Reporting Tri-
als (CONSORT) ﬂow diagram are pro-
vided in supplemental data and
supplemental Fig. 1 (available in an on-
line appendix at http://dx.doi.org/10.
2337/dc08-1206).
Randomization and interventions
Withuseofacomputer-generatedtableof
random numbers, treatment assignments
were made within seven age-groups (45–
49, 50–54, 55–59, 60–64, 65–69, 70–
74, and 75 years) using block sizes of
16. Random assignment took place from
30 April 1993 through 24 January 1996.
Each year, women received calendar
packs that contained amber capsules (vi-
tamin E or placebo) and white pills (aspi-
rin or placebo) on alternate days. Every 6
months for the ﬁrst year and annually
thereafter, they also received follow-up
questionnaires inquiring about compli-
ancewithpill-taking,potentialadverseef-
fects, occurrence of end points, and risk
factors. Study medications were contin-
uedinblindedfashionthroughthesched-
uled end of the trial (31 March 2004).
Compliance
On the basis of self-reported adherence,
compliance, deﬁned as taking at least
two-thirds of their aspirin or matching
placebo tablets, was 76.1% at 5 years and
67.0% at 10 years. Averaged throughout
the trial, compliance was slightly higher
in the placebo (73.7%) group than in the
active (72.5%) group (P  0.004). Non-
trial use of aspirin or aspirin-containing
products on 4 days/month (“drop-ins”)
was 11.6% at 5 years and 19.2% at 10
years. Averaged throughout the trial, it
was somewhat higher in the placebo
(13.0%) group than in the active (12.7%)
group (P  0.10).
Outcomes and follow-up
Details regarding the ascertainment of in-
cident diabetes in the WHS have been re-
ported previously (17). Information on
newly diagnosed diabetes was collected
on every follow-up questionnaire from
baseline through the end of the trial. All
participants were asked annually “In the
past year, were you newly diagnosed with
diabetesmellitus?”Subjectsalsoprovided
the month and year of diagnosis. Conﬁr-
mation of diabetes was conducted in a
blinded fashion using American Diabetes
Association diagnostic criteria (18). Self-
reported cases were investigated by either
telephone interview conducted by a phy-
sician or a previously validated self-
administeredsupplementalquestionnaire
thatinquiredaboutsymptoms,diagnostic
testing, and use of diabetes medications
(19). The response rate was high with
90% of women who reported incident
diabetes responding to either the tele-
phone interview or supplemental ques-
tionnaire.Onthebasisofresponsestothe
supplemental questionnaire, 77.2% of
those with conﬁrmed cases reported use
of antidiabetic agents. Only women with
conﬁrmed cases were analyzed in this re-
port.Becausethevastmajorityofdiabetes
diagnosed at age 45 years is of the type
2 variant, incident diabetes in the WHS is
considered to be type 2 diabetes.
Glucosescreeningrateswereassessed
during follow-up. When asked about
screening for diabetes on the 9-year ques-
tionnaire, 71.8 and 68.2% of nondiabetic
women reported having a fasting glucose
testperformedwithinthepreceding5and
3years,respectively.Screeningrateswere
equivalent between the two treatment
arms: 68.3 versus 68.1% in the preceding
3 years in the aspirin and placebo groups,
respectively (P  0.78). These values are
similar to contemporaneous diabetes
screening rates; among patients in a U.S.
managed care population, the occurrence
of any glucose testing (random or fasting)
over a 3-year period was 71.5% for
women 45 years (20).
Statistical analysis
All primary analyses were performed on
an intention-to-treat basis. We used Cox
proportional hazards models to estimate
the rate ratio (RR) and 95% CIs, compar-
ing event rates in the aspirin and placebo
groups after adjustment for age and other
randomized treatment assignments (vita-
min E and -carotene, which was a com-
ponent of the trial for a median of 2.1
years) (21). The proportionality assump-
tion of constant hazards over time was
tested using an interaction term of aspirin
with the logarithm of time. The diver-
gence of diabetes incidence over time be-
tween groups was estimated using
Kaplan-Meiersurvivalcurvesandthelog-
rank test was computed to compare
curves.
Exploratory subgroup analyses were
conductedtoexaminetheeffectofaspirin
according to the baseline presence of ma-
jor risk factors for type 2 diabetes includ-
ing age-group, BMI group, family history
of diabetes in a ﬁrst-degree relative, phys-
ical activity, menopausal status, and hor-
mone therapy. Categories are speciﬁed in
Table 1. Among women providing base-
line blood specimens (n  27,167), sub-
group analyses were performed after
stratiﬁcation by levels of total cholesterol,
LDL cholesterol, HDL cholesterol, the to-
tal cholesterol–to–HDL cholesterol ratio,
non-HDL cholesterol, A1C, and high-
sensitivity C-reactive protein (hsCRP).
To estimate the effect of treatment
duration, we ﬁt two separate propor-
tional hazards models to the experience
of the ﬁrst 5 years and after 5 years of
follow-up. To assess the impact of po-
tentially undiagnosed diabetes at base-
line, we conducted sensitivity analyses
in which women with diabetes diag-
nosed during the ﬁrst 2 and 5 years of
follow-up were excluded. To examine
the effect of actual as opposed to as-
signed aspirin use, we performed addi-
tional analyses in which subjects were
censored if and when they stopped tak-
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pills. To assess the effect of nontrial as-
pirin use, we also performed analyses in
whichcensoringoccurredwhenwomen
either stopped taking at least two-thirds
of their study pills or reported outside
use of aspirin or aspirin-containing
products for 4 days/month.
AllanalyseswereperformedwithSAS
(version 9.1; SAS Institute, Cary, NC). A
two-sided signiﬁcance level of 0.05 was
used.
RESULTS— The aspirin and placebo
groups were similar with respect to base-
line characteristics (Table 1). Among
womenprovidingbloodspecimens,there
were also no signiﬁcant differences in
lipid levels, A1C, or hsCRP. The median
duration of follow-up was 10.2 years
(mean 9.8 years). At completion of the
trial, 1,696 cases of conﬁrmed incident
clinical type 2 diabetes had occurred.
There were 849 cases in the aspirin group
and 847 cases in the placebo group, with
no signiﬁcant risk reduction (RR for aspi-
rin versus placebo 1.01 [95% CI 0.91–
1.11]).
The cumulative incidence curves ac-
cording to treatment assignment were
similar throughout follow-up (Fig. 1)
(log-rank P  0.92). A test of the propor-
tionality hazards assumption showed no
deviation from proportionality (P 
0.27). In separate analyses that consid-
ered newly diagnosed diabetes in the ﬁrst
5 years of follow-up versus thereafter, as-
pirintherapywasassociatedwithanRRof
0.99 (95% CI 0.86–1.15) during the ﬁrst
5 years and 1.01 (0.90–1.15) after 5
years. We found no difference when pa-
tients with potentially undiagnosed dia-
betes documented during the ﬁrst 2 or 5
yearsoffollow-upwereexcluded.Inthese
analyses the RRs were 0.99 (0.89–1.09)
and 1.01 (0.90–1.15), respectively.
There was no evidence that any dia-
betesriskfactorsconsideredmodiﬁedthe
effect of aspirin on diabetes incidence
(Table 2) (Pinteraction 0.2 for clinical risk
factors).Althoughwedidﬁndstatistically
signiﬁcant risk reductions among women
who had total cholesterol levels 6.21
mmol/l (RR 0.77 [95% CI 0.61–0.97],
P  0.028) and LDL cholesterol 4.13
mmol/l (0.76 [0.58–1.00], P  0.049),
with borderline nonsigniﬁcant ﬁndings
forwomenwithtotalcholesterol–to–HDL
cholesterolratio6.0(0.81[0.66–1.00],
P  0.053), these ﬁndings must be inter-
pretedwithcautiongivenboththelackof
a consistent risk increase across biomar-
ker categories and the large number of
subgroupsexamined.Therewasnostatis-
ticallysigniﬁcantinteractionforanyofthe
biomarkers assessed (Pinteraction  0.39
for total cholesterol, 0.26 for LDL choles-
terol, 0.13 for the total cholesterol–to–
HDL cholesterol ratio, and 0.2 for all
others).
Because compliance diminished over
time, sensitivity analyses were performed
that censored noncompliant women at
the time they stopped taking at least two-
thirds of their study pills during the pre-
ceding year. In this analysis, there was
also no signiﬁcant beneﬁt of aspirin (RR
1.02[95%CI0.91–1.15]).Whenwomen
were censored at the time they either
stopped taking at least two-thirds of their
study pills or started outside aspirin or
aspirin-containing medications on 4
days/month, ﬁndings were similarly non-
signiﬁcant. In addition, there was no evi-
dence of effect modiﬁcation by other
randomized treatments. With regard to
safety, as expected, there were slightly
higher rates of clinically signiﬁcant bleed-
ing episodes and other side effects in the
aspirin arm compared with placebo: 4.5
vs. 3.7% (RR 1.22, P  0.001) for any
bleeding event, 0.6 vs. 0.4% (RR 1.37,
P  0.03) for transfusion-requiring
bleeding, 2.7 vs. 2.1% (RR 1.30, P 
0.001) for peptic ulcer, 15.2 vs. 14.4%
(RR 1.06, P  0.02) for hematuria, and
19.0 vs. 16.5% (RR 1.17, P  0.001) for
epistaxis.
CONCLUSIONS — In this large-
scale, long-term trial of initially healthy
women, there was no association of 100
Table 1—Baseline characteristics of the study population
Aspirin Placebo
Total population
n 19,326 19,390
Age category (%)
45–54 years 60.6 60.6
55–64 years 29.2 29.2
65 years 10.2 10.1
BMI category (%)
25.0 kg/m
2 51.8 51.8
25.0–29.9 kg/m
2 30.8 31.0
30.0 kg/m
2 17.4 17.2
Ethnicity (%)
White not of Hispanic origin 95.1 95.0
African American 2.3 2.1
Hispanic 1.0 1.1
American Indian or Alaskan Native 0.3 0.2
Asian or Paciﬁc Islander 1.3 1.5
Unknown (none of the above) 0.2 0.2
Family history of diabetes (%)* 24.6 25.1
Current smoker (%) 12.9 13.4
Exercise  once weekly (%)† 42.4 41.8
Alcohol consumption  once weekly (%) 42.4 42.5
History of hypertension (%) 24.9 24.7
History of hyperlipidemia (%) 29.5 28.5
Postmenopausal (%) 54.6 53.9
Baseline use of hormone therapy (%) 41.6 40.9
Available baseline blood specimen
n 13,595 13,572
Total cholesterol (mmol/l) 5.41 (4.76–6.10) 5.38 (4.76–6.08)
LDL cholesterol (mmol/l) 3.15 (2.60–3.74) 3.13 (2.60–3.72)
HDL cholesterol (mmol/l) 1.35 (1.13–1.62) 1.35 (1.12–1.61)
Total cholesterol–to–HDL cholesterol ratio 4.0 (3.2–4.9) 3.9 (3.2–4.9)
Non-HDL cholesterol(mmol/l) 3.99 (3.33–4.72) 3.98 (3.34–4.68)
A1C (%) 5.0 (4.8–5.2) 5.0 (4.8–5.2)
hsCRP (mg/l) 2.0 (0.8–4.2) 2.0 (0.8–4.3)
Data are % or median (interquartile range). *Family history of diabetes in a ﬁrst-degree relative (mother,
father, sister, or brother). †Physical activity deﬁned by number of episodes of vigorous physical activity per
week.
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overall incidence of clinical type 2 diabe-
tes. Treatment duration, 5 years or 5
years, did not have an impact on our re-
sults,andthetreatmenteffectdidnotvary
signiﬁcantly across subgroups of women
at high risk for diabetes due to the pres-
ence of clinical risk factors, dyslipidemia,
elevated A1C, or hsCRP. There was no
difference when women with early cases,
presumably undiagnosed at baseline,
were excluded or in analyses accounting
for adherence to randomized assignment.
Aspirin therapy was associated with a
higher incidence of clinically important
bleeding events.
The increasing incidence of diabetes,
high treatment costs, and disproportion-
ate impact on cardiovascular disease in
womenhighlighttheneedtoidentifypre-
vention strategies applicable on a broad
population basis. Preventive measures
with potential dual effects on cardiovas-
cular and diabetes risk reduction are
particularly appealing because “cardiom-
etabolic” risk factors often coincide in the
same individual. The main ﬁndings of the
Women’s Health Study were published
previously and demonstrated that long-
term treatment with low-dose aspirin, al-
though resulting in no signiﬁcant beneﬁt
or harm on the end point of any ﬁrst ma-
jor cardiovascular event, did signiﬁcantly
reduce the risk of stroke overall (RR 0.83
[95% CI 0.69–0.99]) and myocardial in-
farction among women aged 65 years
(0.66 [0.44–0.97]) (13). The current
analysisaddressestheimportantquestion
of whether low-dose aspirin has added
beneﬁts for diabetes prevention in this
large population of otherwise healthy
women. This report provides the only
randomized data available in this regard.
One of the least appreciated pharma-
cological actions of aspirin is its ability to
lower glucose levels. Attempts to delin-
eate this effect have been made in several
smallclinicalstudies.Amongbothnondi-
abetic and diabetic patients, short-term
high-dose aspirin (3–10 g/day for up to 3
weeks) is consistently associated with
higher basal and stimulated insulin con-
centrations and reduced glucose excur-
sion during glucose tolerance testing (8–
10,22). However, whether aspirin has a
net beneﬁcial contribution to glucose ho-
meostasis has been controversial, with
several studies suggesting that any favor-
able hypoglycemic action is offset by de-
terioration in insulin sensitivity (23,24).
Higher doses of aspirin given over a
longer period were more recently found
to have broad therapeutic beneﬁts in a
detailed study of nine patients with overt
type 2 diabetes (10). At the end of 2
weeks,aspirinatadoseof7g/daylowered
fasting glucose (25%) and C-reactive
protein (15%) while improving glucose
tolerance(20%),reducingbasalhepatic
glucose production (20%), and increas-
ing insulin-stimulated peripheral glucose
uptake (20%). Importantly, however, the
high dose of aspirin used in all of these
studies is known to cause serious side
effects.
The current analysis directly evalu-
atedwhetheralowdoseofaspirinaccept-
able for long-term use in routine clinical
practice is effective in reducing clinical
type 2 diabetes. Although we found no
evidence to support this approach, there
are three main possibilities that could ac-
count for our null results. First, the dose
of aspirin used in this study may be insuf-
ﬁcient to impart a clinical beneﬁt. As
noted, prior studies evaluating the glu-
cosemetaboliceffectsofaspirinhaveused
far higher doses. Data pertaining to po-
tential hypoglycemic actions of low-dose
aspirinhavenotbeenavailable.However,
short-term treatment with doses as low as
30–81 mg/day have been shown to im-
prove several systemic inﬂammatory pa-
rameters, including lowering soluble
CD40 ligand and promoting counter-
regulatory anti-inﬂammatory mediators
such as 15-epi-lipoxin A4 (11,12). De-
spite these latter ﬁndings, our data dem-
onstrate that chronic treatment with 100
mgaspirinonalternatedaysdoesnotpre-
vent clinical diabetes. However, interme-
diate doses as high as 1.3 g/day have been
used in long-term clinical trials of cardio-
vascular disease prevention, and these
settings may offer additional opportuni-
ties to evaluate this issue if diabetes inci-
dence was also ascertained.
Second, women enrolled in the WHS
were generally at low risk for diabetes as
evidenced by the low prevalence of obe-
sity, predominantly non-Hispanic white
ethnicity, and lower rates of clinical dia-
betes compared with similarly aged
women in the overall U.S. population
(25).Itispossiblethattheuseofaspirinin
ahigherriskgroupmayhaveledtodetec-
tion of a beneﬁcial effect. However, in
subgroup analyses of women with high-
risk features we did not ﬁnd strong sup-
port for differential effects. Furthermore,
there was no beneﬁt among women hav-
ing evidence of inﬂammation as reﬂected
by elevated hsCRP.
Third, underdiagnosis of diabetes
may have inﬂuenced our results. Women
did not undergo systematic screening for
diabetes or glucose intolerance as a part
of the study; thus, we detected clinical
diabetes as ascertained during routine
clinical practice rather than all women
with biochemical evidence of disease.
However, any misclassiﬁcation due to
unrecognized diabetes would be nondif-
ferential between treatment arms and un-
likely to lead to important alterations in
the estimation of relative effects. In addi-
tion, we are reassured that reported dia-
betes screening rates among participants
in our study were similar to contempora-
neous screening rates in the general
population and equivalent in the two
treatment groups.
Major strengths of this analysis in-
clude the randomized setting, large study
Figure 1— Cumulative incidence of type 2 diabetes in the aspirin and placebo groups.
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Characteristic
Sample size
(n)
Aspirin group Placebo group
RR (95% CI)* Pinteraction
No.
events
Events per
1,000
patient-years
No.
events
Events per
1,000
patient-years
Age 0.29
45–54 years 23,473 485 4.2 463 4.0 1.05 (0.93–1.20)
55–64 years 11,317 283 5.1 311 5.6 0.91 (0.77–1.07)
65 years 3,926 81 4.3 73 3.9 1.12 (0.81–1.53)
BMI 0.73
25.0 kg/m
2 19,655 116 1.2 106 1.1 1.10 (0.85–1.43)
25–29.9 kg/m
2 11,713 262 4.6 258 4.5 1.02 (0.86–1.21)
30 kg/m
2 6,563 447 14.5 457 14.9 0.98 (0.86–1.11)
Family history of diabetes† 0.68
No 29,095 462 3.2 463 3.2 0.99 (0.87–1.13)
Yes 9,621 387 8.5 384 8.2 1.04 (0.90–1.19)
Exercise  once weekly‡ 0.35
No 22,414 606 5.6 624 5.7 0.98 (0.88–1.10)
Yes 16,282 243 3.0 222 2.8 1.09 (0.91–1.30)
Hypertension 0.52
No 29,117 409 2.9 398 2.8 1.03 (0.90–1.19)
Yes 9,590 439 9.6 449 9.9 0.97 (0.85–1.11)
Hyperlipidemia 0.75
No 27,492 481 3.6 485 3.6 1.01 (0.89–1.14)
Yes 11,208 366 6.6 362 6.8 0.98 (0.84–1.13)
Menopause and HT 0.63
Premenopausal 10,757 188 3.6 167 3.1 1.14 (0.92–1.40)
Uncertain 6,926 179 5.3 192 5.5 0.96 (0.78–1.18)
Postmenopausal, HT 11,686 210 3.6 214 3.8 0.96 (0.80–1.16)
Postmenopausal, no HT 9,248 268 6.0 271 6.1 0.99 (0.83–1.17)
Total cholesterol 0.38
5.18 mmol/l 11,067 204 3.8 201 3.7 1.03 (0.85–1.25)
5.18–6.20 mmol/l 10,170 242 4.9 231 4.6 1.06 (0.88–1.27)
6.21 mmol/l 5,929 130 4.4 162 5.6 0.77 (0.61–0.97)
LDL cholesterol 0.26
2.59 mmol/l 6,652 130 4.0 127 3.9 1.04 (0.81–1.32)
2.59–3.35 mmol/l 9,806 202 4.3 194 4.0 1.06 (0.87–1.29)
3.36–4.12 mmol/l 6,978 153 4.4 155 4.6 0.97 (0.78–1.21)
4.13 mmol/l 3,731 91 4.9 118 6.5 0.76 (0.58–1.00)
HDL cholesterol 0.86
1.30 mmol/l 11,891 454 8.0 467 8.1 0.98 (0.86–1.12)
1.30 mmol/l 15,275 122 1.6 127 1.7 0.96 (0.75–1.22)
Total cholesterol–to–HDL cholesterol ratio 0.13
4.0 14,027 102 1.5 108 1.5 0.95 (0.73–1.25)
4.0–5.9 10,625 314 6.1 295 5.7 1.07 (0.91–1.25)
6.0 2,513 160 13.5 191 16.6 0.81 (0.66–1.00)
Non-HDL cholesterol 0.29
3.36 mmol/l 7,045 90 2.6 74 2.6 1.20 (0.88–1.63)
3.36–4.12 mmol/l 8,185 141 3.6 155 3.8 0.95 (0.76–1.19)
4.13 mmol/l 11,935 345 5.9 365 6.4 0.92 (0.80–1.07)
A1C 0.16
5.0% 13,797 83 1.2 71 1.0 1.19 (0.86–1.63)
5.0% 13,306 493 7.7 521 8.2 0.93 (0.83–1.06)
hsCRP 0.53
1.0 mg/l 8,250 44 1.1 36 0.9 1.23 (0.79–1.91)
1.0–2.9 mg/l 9,076 130 2.9 140 3.1 0.94 (0.74–1.20)
3.0 mg/l 9,841 402 8.5 418 8.9 0.95 (0.83–1.09)
Data are % unless otherwise indicated. Analyses involving biomarkers are restricted to women providing baseline blood specimens (n  27,167). *RR of clinical
diabetes in the aspirin versus placebo group adjusted for age and randomized treatment assignment to vitamin E and -carotene. †Family history of diabetes in a
ﬁrst-degreerelative(mother,father,sister,orbrother).‡Physicalactivitydeﬁnedbynumberofepisodesofvigorousphysicalactivityperweek.HT,hormonetherapy.
Pradhan and Associates
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large number of events, and ability to ex-
amine several large high-risk subgroups
of women. In addition, baseline blood
specimens were provided by roughly
70% of women in whom hsCRP and A1C
levels were available. Importantly, sys-
tematic data were also collected on the
occurrence of signiﬁcant bleeding events.
Limitations of this study have been al-
luded to previously. An important limita-
tion is the lack of systematic screening for
more sensitive measures of glucose intol-
erance and insulin resistance during fol-
low-up. While the costs associated with
such diagnostic testing are prohibitive in
this large-scale setting, we cannot with
the current data determine the potential
impact of low-dose aspirin on these sub-
clinical markers of incipient disease.
In summary, aspirin at a dose of 100
mg on alternate days is not effective for
the prevention of clinical type 2 diabetes
among otherwise healthy women at gen-
erally low risk for this disease. Our data
do not pertain to other salicylate agents
currently being evaluated for diabetes
treatmentortointermediateorhighdoses
of long-term aspirin in primary preven-
tion. However, even at the low dose eval-
uated in this trial, the use of aspirin was
associated with a signiﬁcant increase in
clinically important bleeding events and
any potential beneﬁt at higher doses, if
found, must take into account this poten-
tial for excess risk.
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